Ramon Lloret, MD
Interventional Cardiology · Miami, FLNPI 1760497507
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Merck at 54.5% of the total. Reporting peaked in 2022 at $18,741 and has fallen 91.2% since, to $1,655 in 2025.
Across 351 payments — averaging $90.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$17K
- Boston Scientific$4K
- Medtronic$3K
- ZOLL Circulation Inc$3K
- AstraZeneca$404
- E.r. Squibb & Sons, L.L.C.$338
- plus $4K from 35 others
Across 29 payments — averaging $6292.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$104K
- Merck$59K
- Novartis$19K
What the payments were for
- Consulting fees$2,5008%
- Speaking & faculty fees$15,01547%
- Travel & lodging$1,8546%
- Food & beverage$12,27239%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$16,780
- Catheter$2,787
- TherOx DS2 Console$2,500
- Downstream Cartridge$2,500
- WATCHMAN FLX$1,176
- COBALT DR MRI SURESCAN$732
- Amplia MRI$506
- CROSSBOSS$459
- OPTIMIZER$356
- WATCHMAN Access System$288
- Temperature Management System$287
- Temperature Management System Start-Up Kit$287
- Micra$174
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$166
- SYMPLICITY G3$164
- MITRIS RESILIA Mitral Valve$153
- Cobalt$153
- AZURE XT DR MRI SURESCAN$152
- STINGRAY$150
- GENERAL VASCULAR ACCESS$150
How this compares
$31,677 in reported general payments places this provider in the 80th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 495 | $603,044 |
| EntrestoSacubitril/Valsartan | 252 | $354,411 |
| Repatha SureclickEvolocumab | 154 | $170,681 |
| FarxigaDapagliflozin Propanediol | 81 | $88,404 |
| VascepaIcosapent Ethyl | 102 | $68,889 |
| XareltoRivaroxaban | 66 | $63,281 |
| MultaqDronedarone Hcl | 32 | $44,275 |
| BrilintaTicagrelor | 37 | $34,906 |
| JardianceEmpagliflozin | 24 | $24,286 |
| Praluent PenAlirocumab | 16 | $17,806 |
| Ezetimibe | 734 | $15,918 |
| Rosuvastatin Calcium | 1,118 | $15,197 |
| CorlanorIvabradine Hcl | 11 | $11,771 |
| OzempicSemaglutide | 11 | $10,090 |
| Metoprolol Succinate | 709 | $9,272 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $159 | $603,044495 claims |
| NovartisEntresto | $211 | $354,411252 claims |
| AstraZenecaFarxiga, Brilinta | $404 | $123,310118 claims |
| Johnson & JohnsonXarelto | $232 | $63,28166 claims |
| Sanofi-aventis U.S. LLCMultaq | $153 | $44,27532 claims |
| Boehringer IngelheimJardiance | $80 | $24,28624 claims |
| AmgenCorlanor | $269 | $11,77111 claims |
| Novo NordiskOzempic | $274 | $10,09011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Miami
- Eduardo de MarchenaMiami$498K
- Juan ZambranoMiami$173K
- Michael DyalMiami$157K
- Nish PatelMiami$149K
- Pedro Martinez-ClarkMiami$136K
- Mauricio CohenMiami$129K
- Marquand PattonMiami$112K
- Ramon QuesadaMiami$94K
- Alvaro GomezMiami$71K
- Vinod ChainaniMiami$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.